The FTC will not challenge Amazon's $3.49B acquisition of One Medical parent company 1Life Healthcare; Amazon CEO Andy Jassy says the deal has closed
The Federal Trade Commission won't challenge Amazon.com Inc.'s $3.49 billion acquisition of One Medical parent 1Life Healthcare Inc. …
Context & Ripple Effects
Amazon’s plan to buy One Medical began as an all-cash primary-care expansion, offering in-person, digital, and virtual services, before the FTC investigation put the transaction under review. The agency’s decision not to challenge it removes the obstacle that had threatened to delay closing.
The acquisition also fits coverage that described One Medical and iRobot as part of Andy Jassy’s search for a fourth pillar beyond AWS, Prime, and Marketplace. Closing turns that strategy from a proposed deal into an owned healthcare asset.
First-order effects
- Amazon can now complete ownership of 1Life Healthcare and One Medical, while the FTC has ended its challenge decision without blocking the transaction.
- Andy Jassy gains a completed healthcare acquisition rather than a pending bet in Amazon’s effort to expand beyond its three established businesses.
Second-order effects
- Primary-care providers and healthcare platforms now face Amazon as the owner of One Medical’s in-person, digital, and virtual-care business, rather than merely a prospective buyer.
- The outcome gives Amazon a cleared reference point for pursuing its broader portfolio strategy, though it does not determine how the FTC will assess its other proposed acquisitions.
Third-order effects
- The deal adds to the pattern of large technology companies seeking growth through adjacent service businesses, with primary care becoming part of Amazon’s portfolio rather than a standalone target.
- FTC review is becoming a central gating step in major platform acquisitions: regulatory clearance can determine whether diversification plans become operating businesses.
The trend: Large platforms are using acquisitions to build new business pillars outside their core markets, while antitrust review increasingly sets the timetable for those moves.